These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7734697)

  • 41. The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status.
    Doglioni C; Dei Tos AP; Laurino L; Chiarelli C; Barbareschi M; Viale G
    Virchows Arch; 1994; 424(1):47-51. PubMed ID: 7981903
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic value of the combined assessment of proliferating cell nuclear antigen immunostaining and nuclear DNA content in invasive human mammary carcinomas.
    Schimmelpenning H; Eriksson ET; Franzén B; Zetterberg A; Auer GU
    Virchows Arch A Pathol Anat Histopathol; 1993; 423(4):273-9. PubMed ID: 7901939
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic value of p53 protein expression in breast carcinomas.
    Hurlimann J
    Pathol Res Pract; 1993 Nov; 189(9):996-1003. PubMed ID: 8302733
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
    Göhring UJ; Scharl A; Ahr A
    Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
    [TBL] [Abstract][Full Text] [Related]  

  • 45. pS2 expression in infiltrating ductal carcinoma of the breast correlates with oestrogen receptor positivity but not with histological grade and lymph node status.
    Looi LM; Azura WW; Cheah PL; Ng MH
    Pathology; 2001 Aug; 33(3):283-6. PubMed ID: 11523925
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic value of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinoma breast.
    Aziz SA; Pervez S; Khan SM; Kayani N; Nasir MI
    J Coll Physicians Surg Pak; 2005 Apr; 15(4):225-9. PubMed ID: 15857596
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Proliferating cell nuclear antigen in breast lesions: correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer.
    Shrestha P; Yamada K; Wada T; Maeda S; Watatani M; Yasutomi M; Takagi H; Mori M
    Virchows Arch A Pathol Anat Histopathol; 1992; 421(3):193-202. PubMed ID: 1357812
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer.
    Toi M; Nakamura T; Mukaida H; Wada T; Osaki A; Yamada H; Toge T; Niimoto M; Hattori T
    Cancer; 1990 May; 65(9):1980-4. PubMed ID: 2372767
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer.
    Tsutsui S; Ohno S; Murakami S; Hachitanda Y; Oda S
    Breast Cancer Res Treat; 2002 Jan; 71(1):67-75. PubMed ID: 11859875
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.
    Esteban JM; Felder B; Ahn C; Simpson JF; Battifora H; Shively JE
    Cancer; 1994 Sep; 74(5):1575-83. PubMed ID: 7914825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relations between epidermal growth factor receptor and oestrogen and progesterone receptors in breast cancers of premenopausal and postmenopausal patients in Kuwait.
    Nasralla MY; Paszko Z; Omar YT; Ali MA; al Jazzaf H; Padzik H; Temmim L
    Eur J Cancer; 1992; 29A(1):76-81. PubMed ID: 1445750
    [TBL] [Abstract][Full Text] [Related]  

  • 52. EGF-R and steroid receptors in breast cancer: a comparison with tumor grading, tumor size, lymph node involvement, and age.
    Zeillinger R; Kury F; Speiser P; Sliutz G; Czerwenka K; Kubista E
    Clin Biochem; 1993 Jun; 26(3):221-7. PubMed ID: 8392451
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases.
    Zafrani B; Aubriot MH; Mouret E; De Crémoux P; De Rycke Y; Nicolas A; Boudou E; Vincent-Salomon A; Magdelénat H; Sastre-Garau X
    Histopathology; 2000 Dec; 37(6):536-45. PubMed ID: 11122436
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical significance of tumor content of epidermal growth factor receptor in breast cancer].
    Mulero M; Fernández Raigoso P; Vázquez J; Lamelas ML; Corte D; Allende MT; Rodríguez JC; Vizoso F
    Rev Esp Med Nucl; 2003 Nov; 22(6):386-94. PubMed ID: 14588231
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of estrogen, progesterone and epidermal growth factor receptors in primary and metastatic breast cancer.
    van Agthoven T; Timmermans M; Dorssers LC; Henzen-Logmans SC
    Int J Cancer; 1995 Dec; 63(6):790-3. PubMed ID: 8847135
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship of DNA ploidy to hormone receptor status and proliferation in invasive breast carcinoma.
    Spiethoff A; Schenck A; Bohrer M
    J Cancer Res Clin Oncol; 2000 Dec; 126(12):707-10. PubMed ID: 11153143
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
    Naidu R; Wahab NA; Yadav MM; Kutty MK
    Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation.
    Bossuyt V; Fadare O; Martel M; Ocal IT; Burtness B; Moinfar F; Leibl S; Tavassoli FA
    Int J Surg Pathol; 2005 Oct; 13(4):319-27. PubMed ID: 16273187
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer.
    Gasparini G; Bevilacqua P; Pozza F; Meli S; Boracchi P; Marubini E; Sainsbury JR
    Br J Cancer; 1992 Nov; 66(5):970-6. PubMed ID: 1419645
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in invasive ductal carcinoma of the breast in Taiwan.
    Chu JS; Huang CS; Chang KJ
    Cancer Lett; 1998 Sep; 131(2):145-52. PubMed ID: 9851246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.